Chapmans’ Syn Dynamics forges important joint venture to progress PHP technology

Published 05-OCT-2017 12:21 P.M.


4 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Diversified investment group, Chapmans Limited (ASX:CHP) announced on Thursday that it had successfully completed the due diligence required to establish a joint venture between its clean-tech business, Syn Dynamics Australia (SDA) and leading APAC region waste and environmental services company, Total Waste Management (TWM), paving the way for the establishment of SDA’s first commercial scale hazardous waste-to-energy plant.

TWM is a world class waste and environmental services company headquartered in Papua New Guinea with its operations focused on the Asia-Pacific region. The company services the petroleum and mining industries, as well as being leverage to a wide range of market segments in the industrial and the commercial sector.

The group’s range of services include cleaning and industrial services, facilities management and civil and environmental engineering.

Joint venture paves the way for commercialisation of PHP technology

The Joint Venture is a significant milestone for SDA and its next-generation plasma gasification technology which converts a wide range of waste material into a high value synthetic gas (syngas).

It formally brings together SDA’s market leading technology with a major waste management operator with the scope to maximise the commercial potential of SDA’s technology. The joint venture company, registered as TWM HAZTEK Holdings Pty Ltd is an equal 50:50 owned entity with equal board representation from both parties.

Highlighting the synergies that will assist the joint venture in developing a commercially viable operation, SDA Director Anthony Dunlop said, “The incorporation of TWM HAZTEK and preparation for our first commercial scale plant is an important milestone for Syn Dynamics and Chapmans, and we are excited to join forces with TWM given the clear alignment of objectives and a strong cultural fit, including a commitment to delivering unique value and service to our customers”.

Those considering this stock shouldn’t make assumptions regarding future sales, nor should they base investment decisions on performances to date. Those considering this stock should seek independent financial advice.

Market leading position in remediating 100 per cent of hazardous waste stocks

CHP’s subsidiary company, Chapmans Opportunities Limited (COL), has a majority, strategic 80 per cent interest in SDA. The group’s breakthrough next generation PHP plasma gasification technology (Plasma Hydrous Pyrolysis) converts a wide range of waste materials into high value syngas.

PHP is able to remediate 100 per cent of hazardous waste feedstock, excluding any residual metals, into non-hazardous products including syngas. Other competing technologies typically achieve significantly lower conversion rates, produce tars and toxic chemicals, as well as requiring exceptionally high energy consumption requirements, effectively limiting their mass scale adoption.

CSIRO conducts extensive testing of PHP and assists with pilot plant

SDA recently completed a very successful 12 month R&D and Commercialisation Project with the Commonwealth Scientific and Industrial Research Organization (CSIRO) which resulted in the validation of the company’s plasma reactor processing as a hazardous waste conversion technology.

As part of the project, SDA engaged CSIRO to conduct a first phase scientific validation program at its Queensland Centre for Advanced Technology (QCAT) facility, which amongst other domains, specialises in gasification processing technologies.

During this critical first phase of commissioning, testing and analysis, CSIRO achieved
major milestones including the establishment of an advanced analytical capability able to quantify reaction results and syngas properties with scientific precision.

In terms of the next phase of the R&D project, SDA has engaged specialist design and process engineering consulting firm Advisian Pty Ltd, a wholly owned subsidiary of global consulting engineering group Worley Parsons Limited (ASX:WOR), to manage the design,
specification, procurement, fabrication and construction of a commercial scale pilot plant at CSIRO’s QCAT facility.

The fact that the CSIRO is advancing its involvement to this stage demonstrates a significant degree of confidence in the technology. The pilot plant will have a throughput capacity of 40 kilograms of waste material per hour and represents a key milestone in the technology development process, providing an essential step between its successful laboratory scale batch processing and the first industrial scale commercial plant.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free